Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’
Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new gold standard for clinical research.
